首页> 外文会议>Conference on Peritoneal Dialysis >A Case of Encapsulating Peritoneal Sclerosis Suspected to Result from the Use of Icodextrin Peritoneal Solution
【24h】

A Case of Encapsulating Peritoneal Sclerosis Suspected to Result from the Use of Icodextrin Peritoneal Solution

机译:一种封装腹膜硬化症的病例,涉及使用Icodextrin腹膜溶液

获取原文

摘要

Encapsulating peritoneal sclerosis (EPS) is an intestinal obstruction syndrome in which peritoneal deterioration and intraperitoneal inflammation result in intestinal adhesions, which are covered with a fibrin capsule and which cause bowel obstruction. Here, we report the case of a patient with EPS suspected to result from the use of icodextrin peritoneal solution. In this patient, peritoneal permeability to high molecular weight solutes and effluent interleukin-6 (IL-6) levels increased after initiation on-to icodextrin solution. The patient developed symptoms of intestinal obstruction accompanied by intestinal edema 30 months after the start of icodextrin and after a peritoneal dialysis (PD) duration of 78 months. He was then diagnosed as being in a pre-EPS state. The use of icodextrin solution was discontinued, and the symptoms of intestinal obstruction improved after corticosteroid administration. Subsequently, he was managed on a combination of PD using glucose solution low in glucose degradation products and of twice-weekly hemodi-alysis, but he showed enhanced peritoneal permeability and increases in effluent IL-6. After a PD period of 98 months, severe symptoms of intestinal obstruction developed, and enteroly-sis was performed. The degeneration of the intestinal wall itself was slight, and the adhesions between the capsule and intestinal surface could be readily removed. In this patient, the degree of peritoneal deterioration and capsule formation differed from that of typical EPS. These findings suggest the promotion of capsule formation by icodextrin solution and the involvement of certain inflammatory reactions.
机译:封装腹膜硬化(EPS)是肠阻塞综合征,其中腹膜恶化和腹膜内炎症导致肠粘连,其覆盖有纤维蛋白胶囊和引起肠梗阻。在这里,我们报告与EPS怀疑因使用艾考糊精腹膜液导致患者的情况下。在该患者,腹膜渗透性高分子量溶质和流出物白介素-6(IL-6)水平开始后增加了对艾考糊精溶液。肠梗阻的病人出现症状伴随着艾考糊精的开始30个月后和78个月,腹膜透析(PD)时间后肠道水肿。然后,他被诊断为预EPS状态。使用艾考糊精溶液停产,肠梗阻症状皮质类固醇后好转。随后,他被使用葡萄糖溶液在低葡萄糖降解产物和每周两次hemodi-alysis的PD的组合管理的,但他表现出增强腹膜通透性和在流出物IL-6增加。经过98个月的PD期间,肠梗阻症状严重开发,并进行enteroly-SIS。肠壁本身的变性是轻微的,并且胶囊和肠表面之间的粘连可以容易地除去。在该患者,腹膜恶化和胶囊形成的程度从该典型EPS的不同。这些结果表明通过艾考糊精溶液和某些炎症反应的参与促进胶囊形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号